« Back
Home /
Gliclazide

Gliclazide

Item no.	HY-B0753-500mg
Manufacturer	MedChem Express
CASRN	21187-98-4
Amount	500 mg
Quantity options	10 mM/1 mL 1 g 500 mg 5 g
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.96
Citations	[1]Shimoyama, T., et al., Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation. Metabolism, 2006. 55(6): p. 722-30.\|[2]Lawrence, C.L., et al., Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells. Diabetologia, 2001. 44(8): p. 1019-25.
Smiles	O=S(C1=CC=C(C)C=C1)(NC(NN2CC3C(CCC3)C2)=O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	S1702,SE1702
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	Potassium Channel
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	323.41
Product Description	Gliclazide (S1702) is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC50 of 184 nM. Gliclazide is used as an antidiabetic[1].
Manufacturer - Research Area	Cardiovascular Disease
Solubility	DMSO: ≥ 100 mg/mL\|H2O: < 0.1 mg/mL
Manufacturer - Pathway	Membrane Transporter/Ion Channel
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-B0753-500mg-safety-datasheet.pdf